A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).


Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan; Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan. Electronic address: [Email]


Human epidermal growth factor 2 (HER2) is a potential driver oncogene. Although HER2-targeted precision therapy has been tested in non-small cell lung cancer (NSCLC), the demographic characteristics of HER2-positive NSCLC have not been systematically defined.


fluorescence in situ hybridization,human epidermal growth factor 2,immunohistochemistry,mutation,non-small cell lung cancer,